BR112018071108A2 - antígenos e anticorpos de chagas e composições, métodos e usos dos mesmos - Google Patents

antígenos e anticorpos de chagas e composições, métodos e usos dos mesmos

Info

Publication number
BR112018071108A2
BR112018071108A2 BR112018071108-0A BR112018071108A BR112018071108A2 BR 112018071108 A2 BR112018071108 A2 BR 112018071108A2 BR 112018071108 A BR112018071108 A BR 112018071108A BR 112018071108 A2 BR112018071108 A2 BR 112018071108A2
Authority
BR
Brazil
Prior art keywords
antigens
methods
compositions
nasturtium
antibodies
Prior art date
Application number
BR112018071108-0A
Other languages
English (en)
Inventor
Pleguezuelos Mateo Olga
Romero Caparros-Wanderley Wilson
Alan Stoloff Gregory
Original Assignee
Peptcell Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Limited filed Critical Peptcell Limited
Publication of BR112018071108A2 publication Critical patent/BR112018071108A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

o presente relatório descritivo descreve antígenos de trypanosoma, composições imunogênicas e medicamentos compreendendo tais antígenos de trypanosoma, métodos e usos para tais antígenos de trypanosoma e composições imunogênicas para tratar uma doença baseada em trypanosoma.
BR112018071108-0A 2016-04-14 2017-04-18 antígenos e anticorpos de chagas e composições, métodos e usos dos mesmos BR112018071108A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14
US62/322,770 2016-04-14
PCT/EP2017/059189 WO2017178660A1 (en) 2016-04-14 2017-04-18 Chagas antigens and antibodies and compositions, methods and uses thereof

Publications (1)

Publication Number Publication Date
BR112018071108A2 true BR112018071108A2 (pt) 2019-02-26

Family

ID=58671580

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071108-0A BR112018071108A2 (pt) 2016-04-14 2017-04-18 antígenos e anticorpos de chagas e composições, métodos e usos dos mesmos

Country Status (18)

Country Link
US (2) US10973897B2 (pt)
EP (1) EP3442569A1 (pt)
JP (1) JP2019513797A (pt)
KR (1) KR20190039022A (pt)
CN (2) CN116059330A (pt)
AU (1) AU2017248680A1 (pt)
BR (1) BR112018071108A2 (pt)
CA (1) CA3020856A1 (pt)
CL (2) CL2018002932A1 (pt)
CO (1) CO2018012295A2 (pt)
CU (1) CU20180127A7 (pt)
EC (1) ECSP18079073A (pt)
MX (1) MX2018012504A (pt)
NI (1) NI201800105A (pt)
PE (1) PE20190104A1 (pt)
RU (1) RU2018139865A (pt)
SG (1) SG11201808915YA (pt)
WO (1) WO2017178660A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2594637B (en) * 2019-01-07 2023-08-02 Genome Res Ltd Novel trypanosomal vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (de) * 1977-07-12 1979-01-25 Behringwerke Ag Chagas impfstoff und verfahren zu dessen herstellung
ES2169995B1 (es) 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9804158B2 (en) 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
CN116059330A (zh) 2023-05-05
AU2017248680A1 (en) 2018-11-22
ECSP18079073A (es) 2019-02-28
EP3442569A1 (en) 2019-02-20
WO2017178660A1 (en) 2017-10-19
CN109310747A (zh) 2019-02-05
CL2021001441A1 (es) 2021-11-19
MX2018012504A (es) 2019-08-29
CA3020856A1 (en) 2017-10-19
JP2019513797A (ja) 2019-05-30
PE20190104A1 (es) 2019-01-15
WO2017178660A9 (en) 2017-12-07
CU20180127A7 (es) 2019-08-06
US20210220453A1 (en) 2021-07-22
SG11201808915YA (en) 2018-11-29
NI201800105A (es) 2019-02-18
US10973897B2 (en) 2021-04-13
US20170296637A1 (en) 2017-10-19
CL2018002932A1 (es) 2019-02-01
KR20190039022A (ko) 2019-04-10
CN109310747B (zh) 2022-11-22
CO2018012295A2 (es) 2019-04-30
RU2018139865A (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
GB2541571A (en) Pharmaceutical compositions
BR112016019071A2 (pt) método para preparar uma célula t engenheirada, célula t engenheirada, e seus usos
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
BR112018008103A2 (pt) análogos de celastrol
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017024039B8 (pt) Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
BR112017021194A2 (pt) compostos espirocíclicos
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112017002629A2 (pt) decoys de oligonucleotídeo para o tratamento de dor
BR112017008097A2 (pt) método para tratar condições oculares
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
EA201691493A1 (ru) Замещенные n-арилпиридиноны
EA201891419A1 (ru) Пептид-олигонуклеотидные конъюгаты

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]